Menu
Search
|

Menu

Close
X

Albireo Pharma Inc ALBO.OQ (NASDAQ Stock Exchange Capital Market)

25.68 USD
-- (--)
As of Nov 15
chart
Previous Close 25.68
Open --
Volume --
3m Avg Volume 15,589
Today’s High --
Today’s Low --
52 Week High 39.67
52 Week Low 22.23
Shares Outstanding (mil) 8.88
Market Capitalization (mil) 197.28
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.43 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
12
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-2.543
FY17
-2.654
FY16
-6.446
FY15
-16.515
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
17.36
5.95
Price to Book (MRQ)
vs sector
2.61
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
2.56
17.74
LT Debt to Equity (MRQ)
vs sector
0.00
13.15
Return on Investment (TTM)
vs sector
-38.95
14.22
Return on Equity (TTM)
vs sector
-39.21
15.99

EXECUTIVE LEADERSHIP

David Chiswell
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Ronald Cooper
President, Chief Executive Officer, Director, Since 2016
Salary: $460,000.00
Bonus: --
Simon Harford
Chief Financial Officer, Treasurer, Since 2018
Salary: --
Bonus: --
Jan Mattsson
Chief Operating Officer, Since 2016
Salary: --
Bonus: --
Martha Carter
Chief Regulatory Officer, Since 2016
Salary: $355,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10 Post Office Square, Suite 502
BOSTON   MA   02109

Phone: +1857.2545555

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).

SPONSORED STORIES